OncologyEducation· @OncEd · X·· 2 天前评分70
正文 · 机器翻译
Dirk Schadendorf 医学博士谈 III 期 STARBOARD 研究：BRAF V600 突变型黑色素瘤一线 encorafenib、binimetinib 和 pembrolizumab 对比 placebo 和 pembrolizumab。#ESMO26
立即观看：https://bit.ly/4BtJChb
15 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
2071O按 Proffered paper: Melanoma and other skin tumours 对上
STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.org来源：OncologyEducation · x.com